JNJ Johnson & Johnson Earnings and EPS analysis

EPS in 2025 (TTM): $9.41

Last Report Period Date: Jun 29, 2025

As of July this year, based on Johnson & Johnson's most recent financial report, the company's trailing twelve months EPS is $9.41. Johnson & Johnson's earnings per share in 2024 was reported at $5.84, marking a decline from $13.88 in 2023. Johnson & Johnson's EPS for the quarterly period ending on Jun 29, 2025 came in at $2.3.

JNJ earnings history

Historical annual and quarterly earnings per share (EPS) data for Johnson & Johnson
EPS (TTM)
$9.41
EPS Growth YoY (Quarterly)
17.9%
EPS (Quarterly)
$2.3
EPS Growth (Quarterly)
-49.7%

The yearly earnings per share during 2024 was $5.84, a decline of 57.9% compared to $13.88 recorded in 2023. The quarterly earnings per share for the period ending Jun 29, 2025, was $2.3, showing a 17.9% increase compared to the same quarter last year. The trailing twelve months EPS for JNJ is $9.41 as of June 2025. Johnson & Johnson's full-year EPS for 2023 was $13.88, a 103.2% rise compared to the previous year.

JNJ EPS growth

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
17.9%
EPS growth YoY
-57.9%
EPS growth 3Y avg
-9.7%
EPS growth 5Y avg
0.4%

In the past 12 months, Johnson & Johnson has recorded an earnings per share growth rate of 17.9% (YoY, quarterly). Across the past three years, the company had an average EPS annual growth rate of -9.7% per year. In the last five years, the company had an average annual EPS growth of 0.4%. When assessed over a ten-year period, JNJ's average EPS annual growth was 0.1%.

JNJ Earnings Waterfall

Breakdown of revenue, profit and net income for Johnson & Johnson

JNJ Earnings vs Peers

What are the earnings of JNJ compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
MRK Merck & Co Inc 12.29 4,728.6% 9.4% 12%
ABT Abbott Laboratories 16.32 133.8% 24.5% 29.9%
NVS Novartis AG 16.94 -17.2% -17.9% 2.9%
PFE Pfizer Inc 17.82 273.7% -28.7% -13.2%
JNJ Johnson & Johnson 17.82 -57.9% -9.7% 0.4%
GILD Gilead Sciences Inc 24.4 -91.6% -57.5% -38.3%
MDT Medtronic plc 25.57 31% -1.1% 0.3%
SYK Stryker Corp 53.46 -5.8% 14.1% 7.1%
LLY ELI LILLY & Co 65.33 102.1% 24.1% 5.7%

All data is based on quarterly TTM periods, unless otherwise specified.